

The clinical importance of emerging ESKAPE pathogens in nosocomial infections

Masoumeh Navidinia ^{1,*}

¹Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

*Correspondence author: email address:dr.navidinia@sbmu.ac.ir (M. Navidinia)

ABSTRACT

In the last decade, along with the problem of nosocomial infections, multidrug-resistant bacteria in community and hospitals have soared. High frequencies of multidrug-resistant bacteria have been grouped under the acronym ESKAPE: *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Enterobacter spp.* The ESKAPE pathogens are responsible for the majority of nosocomial infections and capable of 'escaping' the biocidal action of antimicrobial agents. The objective of this review is to consider the clinical importance of emerging of ESKAPE pathogens in nosocomial infections to prepare feasible data about tracing and treatment of infection related to ESKAPE pathogens that may be beneficial to clinicians at the bedside. It can be said that healthcare-associated, community-acquired, and nosocomial infections should be clearly considered annually. The awareness of residential antimicrobial resistance can support selecting a convenient empirical therapeutic diet in diseases due to ESKAPE pathogens.

Keywords: Nosocomial infection; ESKAPE pathogens; Antibiotic resistance

INTRODUCTION

One of the most important health concerns is antimicrobial resistance. In the last decade along with the problem of nosocomial infections, the presence of multidrug-resistant bacteria in community and hospitals has been increased. High frequencies of multidrug-resistant bacteria have been grouped under the acronym *ESKAPE*: *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Enterobacter spp.* (1-3). The *ESKAPE* pathogens are responsible for the majority of nosocomial infections and capable of 'escaping' the biocidal action of antimicrobial agents. [2, 4, 5] Antibiotics have greatly influenced life on earth since 1930s. Four decades of extravagant antibiotic utilization had practicable selective pressure on high-level antimicrobial resistance and multiple-drug resistance (MDR) antibiotics caused threats to the end of the "antibiotic period". [2- 5] The common response to rising resistance has been followed by

the proper preface of a novel class of antibiotics production. In a fundamental decrease in new antimicrobials production, generation rate currently fails to keep rise in resistance worldwide. [7]It has been predicted that the lack of proper combination of antibiotics would have miscellaneous ramifications on universal criteria, public health, security and international political consistency. [8]Health authorities, such as the Infectious Diseases Society of America (IDSA), the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO), have enhanced industrial incentives in an attempt to arouse research into novel antimicrobial combination, ameliorate antibiotic surveillance force to cover the remaining therapeutic options to physicians and encourage a focused, concerted endeavor against life-threatening infections due to multidrug-resistant (MDR) and pandrug-resistant Gram-negative bacteria. [4, 8-12]Empiric antibiotic

therapy can ameliorate patients with infections due to these microorganisms. [13, 14] Yet, most studies indicated that improper antimicrobial therapy can be decreased through using an empiric combination therapy. However the combination therapy consist the potential for a synergistic consequences and detention of resistance appearance. [15- 18] Synergy is a microbiological description well-known in in-vitro study. Prohibition of subsequent resistance in some pathogens such as *Pseudomonas aeruginosa* can be postponed by the use of the in-vitro combinations of levofloxacin and imipenem (IMP). [19, 20] No clinical studies on combination therapy in infections due to Gram-negative bacteria have formally tested or demonstrated this hypothesis. [21] Combination diets that contain aminoglycosides have been shown to develop for ***Enterococcus faecium***

Enterococci are gram positive cocci that distribute extensively in nature such as grounds, water, plants, and food, and are normal flora of human and animal enteric tract. [24] Due to their capability to survive under contrary environmental conditions, Enterococci have an accepted function in meat and dairy products and is used as probiotics in food and biological maintainer. [25, 26] Enterococci are opportunistic bacteria which cause severe infectious diseases. [27] Some strains of this genus are resistance to a broad number of antimicrobial drugs; these strains show inherent and acquired antimicrobial resistance. [28] The resistance characteristics can transfer intragenus horizontally or phylogenetically between related genus. [29] Enterococci can obtain resistance to erythromycin, glycopeptides, tetracycline, vancomycin (vancomycin - resistant enterococci; VRE), aminoglycosides (high-level resistance; HLR), gentamicin (high-level resistance gentamicin; HLGR) and streptomycin (high-level resistance streptomycin; HLSR). [30] In Europe, HLR enterococci have been recovered from dairy and meat products as well as strains with multiple antimicrobial resistances, containing vancomycin. [31-33] Various reports have demonstrated that *Enterococcus faecalis* and *Enterococcus faecium* can cause several infections including septicemia,

higher toxicity rates in patient such as nephrotoxicity than monotherapy diet. In patients with sepsis due to Gram-negative who are often volume depleted, metabolic acidosis is present and they are faced with other nephrotoxic agents. [22]

Combination therapy is mostly used in the clinical workout and depends on the orientation of infectious disease doctors, combining the antimicrobial treatment, especially over tuberculosis, HIV infection, brucellosis, *C. difficile*-associated colitis, enterococcal endocarditis, and *Helicobacter pylori* infection. [23] The objective of this review is to consider the clinical importance of emerging ESKAPE pathogens in nosocomial infections to prepare the feasible data on tracing and treatment of infections related to ESKAPE pathogens . urinary tract infections, endocarditis, bacteremia, wound infections, meningitis, and neonatal sepsis [34-36]. Moreover, the simultaneous emergence of VRE and HLAR is a persisting clinical problem in health care facilities. [37-39]

There are nine vancomycin resistance genes including *van A*, *B*, *C*, *D*, *E*, *G*, *L*, *M*, and *van N* in Enterococci. *Van A* is the most common type worldwide [41-45] mainly related to vancomycin resistant *Enterococcus faecium*, allowing a great rate of vancomycin and teicoplanin resistance [46] and *Van B* causes a high degree of vancomycin resistance, yet susceptible to other glycopeptides such as teicoplanin [47,48]. Nosocomial infections due to Enterococci have been introduced extensively all over the world. The Significant reason for long-term permanence of enterococci in the hospital is their inherent resistance to multiple antibiotics generally used and the resistance to novel generation of antibiotics via either gene mutation or transmission of plasmids and transposons. Moreover, enterococci can transfer the vancomycin resistance genes to another species as well as to other genus. Also, the transmission of vancomycin resistant gene from *Enterococcus* to *S.aureus* has been detected in the laboratory. The emergence of vancomycin- intermediate (VISA) and vancomycin-resistant *Staphylococcus aureus* (VRSA) can produce important problems to the

treatment of *S.aureus*. since vancomycin has been considered as a drug of choice for treatment of enterococcal and MRSA infections. *Enterococcus faecium* also causes nosocomial infections. Emergence of vancomycin resistant strains has been related to further charge on the patients, physicians and health setting. Appropriate application of antibiotics against vancomycin resistant *Enterococcus faecium* (VREF) would help designing methods for pathogens control. [49] Recently, there is no current therapy that consistently provides bactericidal activity for critical infections due to VRE. The efficacy of therapy remains problematic because VRE is frequently related to violent underlying diseases and can be a part of polymicrobial infection. [50, 51]

Staphylococcus aureus

Nearly 25 - 30% of skin or noses of healthy people are colonized by *Staphylococcus aureus*. Methicillin-resistant *S. aureus* (MRSA) is resistant to certain antibiotics, such as methicillin, dicloxacillin, oxacillin, cloxacillin, nafcillin, and closely related class of drugs, such as cephalosporins. The use of more powerful drugs than necessary for less serious infections may be some of the causes of the MRSA expansion.

MRSA isolates which are susceptible only to glycopeptides antibiotics, such as vancomycin, are becoming multidrug-resistant. [52] Now, low level resistance to vancomycin is emerging and increasing. [53]

The possible predisposing factors of MRSA emergence are: consumption of antibiotics without medical prescription, lack of awareness, receipt of antibiotics before coming to the hospital, long duration of hospitalization, etc. [54] Infected patients and health care providers' carriers play a significant role in spreading and transferring this badbug in hospitals. [55] Studies on MRSA surveillance in hospitals and communities represent the main challenges of the healthcare setting. [56] Unfortunately, penicillin resistant bacteria can spread in healthcare setting and in the community. Methicillin narrow spectrum semi-synthetic penicillin was introduced to overcome infections due to beta-lactamase-producing *S. aureus*. Strains isolate from the hospital are named as hospital acquired *S. aureus*

(HASA). [57, 58] Clindamycin, a macrolide-lincosamide-streptogramin B (MLSB) antibiotic, is a good substitute to treat these infections. Unfortunately, a diversity of *erm* genes, with either constitutively (MLS_{Bc} phenotype) or inducibly (MLS_{Bi} phenotype) expression can cause resistance to macrolide (MLSB). Active efflux pump, produced by *msrA* gene (MS phenotype), is another resistance mechanism. The treatment of serious bacterial infections with clindamycin may result in failure, therefore detection of this resistance by D test (double disc diffusion test) is a necessity. Laboratory susceptibility test for clindamycin cannot detect routinely inducible clindamycin resistance and erythromycin resistant - clindamycin sensitive strains. [59, 60] *Staphylococcus aureus* causes atopic dermatitis (AD) and induces skin inflammation by secreting superantigens following a chronic relapsing course and defects in innate and acquired immune response resulting in a heightened susceptibility to bacterial, viral and fungal infections. [61-67] The high rate of *S.aureus* colonization in the nasal cavity and skin lesions of AD patients has been reported, especially in ranges between 76–100%, compared to 2–25% in healthy people. [68-70] It might be so that a combination of host factors containing skin barrier disorders and impaired host immune responses in AD patients are the major factors in this respect. [71, 72] Oxacillin-resistant staphylococci are resistant to all beta-lactam antimicrobial drugs except newer cephalosporins with anti-MRSA activity. Thus, susceptibility or resistance to a broad spectrum of beta-lactam drugs may be decreased due to susceptibility tests such as penicillin, cefoxitin or oxacillin. Routine testing of other penicillins, cepheps, beta-lactam/beta-lactamase inhibitor combination, or carbapenems is not recommended. A forecast of the existence of *mecA*-related oxacillin resistance in *S.aureus* and *S.lugdunensis*, examination of either cefoxitin disk diffusion or cefoxitin MIC tests can be used. The cefoxitin disk diffusion test is preferred for the purpose of detecting of *mecA*-mediated oxacillin resistance for coagulase – negative staphylococci except *S.lugdunensis*. Cefoxitin is a substitute for tracing of oxacillin resistance, reporting oxacillin as susceptible or

resistant based on cefoxitin results. If a penicillinase –stable penicillin is examined, oxacillin is the preferred agent, and results can be used to the other penicillinase -stable penicillins, dicloxacillin, flucloxacillin and cloxacillin. [73]

Klebsiella pneumonia

Klebsiella pneumonia belonged to the Enterobacteriaceae family that frequently causes lower respiratory tract infection and catheter-associated urinary tract infection.

Klebsiella pneumonia is progressively resistant to penicillin and ampicillin because of its beta-lactamases. In addition, the bacterium belongs to the extended-spectrum beta-lactamase or ESBL strains and is increasingly multidrug-resistant to a wide spectrum such as cephalosporin or ceftazidim. [74]

The emergence of *Klebsiella pneumonia* isolates producing carbapenemases (KPCs) has become a major obstacle in the last 5 years. Carbapenemases are able to destroy the carbapenems and cause resistance against a wide spectrum of antibiotics. [75-78] Recently, many areas in the world have been affected and KPC-producing strains have now been detected from many countries such as China, France, Norway, Brazil, Sweden, Scotland, Trinidad, Colombia, Poland and Tobago, Columbia, occupied Palestine, Greece and Puerto Rico. [79-89] KPC-1 beta - lactamase was created because of a great plasmid that was responsible for the resistance carbapenems, extended-spectrum cephalosporins and aztreonam. [90,91]The fast propagation of bacterial resistance is perhaps due to the *bla*- KPC gene carriage on plasmids. Plasmid-mediated imipenem-hydrolyzing enzyme (KPC-2) among multiple carbapenem resistant bacteria is increasing. [92]

Currently, a predominant isolate and sequence type 258(ST258) is identified to cause about 70% of *K. pneumoniae* infections .[93]It is forecasted that resistance due to KPC will be a mechanism of multidrug-resistance in Gram-negative bacilli in the nearby future. [94,95]The increasing interest on combination therapy for *K. pneumoniae* infections is due to its ability to obtain resistance to distinct classes of antibiotics, containing carbapenems, with limited accessibility of impressive agents. The increasing rate and high

mortality of infections have prompted physicians to consumption combination therapy even more often for the handling of infections because of such bacteria. [96]

Acinetobacter baumannii

Acinetobacter baumannii is an opportunistic bacterial pathogen with the power of causing hospital acquired infections, individually in intensive care units, urinary tract infection, bacteremia, meningitis, pneumonia, wound infections, healthcare-related infections (HAIs) with multiple outbreaks. [97-102]

From January 2002 to August 2004, bloodstream infections due to *A. baumannii* were detected among 85 soldiers in Afghanistan and the Iraq/Kuwait area. A total of 35 % of the strains were susceptible to just one class of antibiotics and 4 % were resistance to all standard drugs.[103] The epidemic potential and the clinical severity of *A. baumannii* infections are primarily related to the capability to survive and propagation in healthcare setting and to expand resistance to a diversity of antimicrobial agents, containing fluoroquinolones, broad-spectrum beta-lactams, and carbapenems.[107-109]

Antimicrobial resistance causes major limits to treatment options in infected patients, particularly in isolates with carbapenems resistant. Other therapeutic options contain aminoglycosides, sulbactam, tigecycline, and polymyxins. [110,111] Spread of *A. baumannii* in a hospital setting is facilitated both by tolerance to desiccation and development of bacterial resistance through antibiotic selective pressure. [112] Antimicrobial resistance causes major limits to the choice of antibiotics in patients infected by carbapenems resistant isolates.[113]MDR *A.baumannii* is resistant to 3 or more several classes of antibiotics containing beta-lactams, aminoglycosides, fluoroquinolones, and 3rd generation of cephalosporin .[114] Pan-drug resistance (PDR) *A.baumannii* was described as the strains that were resistant to all examined antibiotics exclude colistin and tigecycline .[115]

Pseudomonas aeruginosa

One of gram negative bacteria that has intrinsic resistance characteristic is *Pseudomonas aeruginosa*. Low antibiotic susceptibility in this bacteria is due

to low penetrance of the bacterial cellular envelopes, function of multidrug efflux pumps, mutations in targets of antibiotics and the horizontal gene transfer of antibiotic resistance determinants. [116-120]

The outcomes of infection caused by MDR *Pseudomonas* may be related to enlarge morbidity and mortality, which can cause narrow effective antimicrobial choices as resistance to at least three classes of antibiotics, mainly carbapenems, antipseudomonal penicillins, cephalosporins, aminoglycosides, and fluoroquinolones. [120-122]

One of the most common lethal genetic diseases due to *Pseudomonas aeruginosa* in the white population is cystic fibrosis (CF), with the prevalence of 1 case per 90,000 in Asia. [123-125]

If this disorder is almost treated, the average prospects of life expectancy of CF patients would increase more than 35 to even 50 years. [126] *P. aeruginosa* that infects CF patients has serious implications for infection control in the hospital. [127]

Wide range of antimicrobial resistances in MDR *P. aeruginosa* mainly cause the dose limits for remediation such as polymyxins and aminoglycosides. Recent studies have reported that these agents may or may not be as efficient as first-line drugs; and yet, they may also be related to more serious detrimental effects (such as neurotoxicity, ototoxicity and nephrotoxicity). [128-137]

P. aeruginosa is the most studied pathogen about the priority of combination therapy over monotherapy. [138-140] Other prospective studies and meta-analysis have been unsuccessful to demonstrate the priority of the combination therapy versus monotherapy for the treatment of *P. aeruginosa* infections. [141-143]

Serious infections such as burn wounds due to by *Pseudomonas aeruginosa* are treated through the combination of a beta-lactam drugs and an aminoglycoside. The emergence of MDR in *Pseudomonas aeruginosa* containing resistance to β -lactams, aminoglycosides, and fluoroquinolones is extremely problematic to the treatment of burn patient. So, the recognition of drug resistance patterns in *P. aeruginosa* and

tracing of pan-resistant producing bacteria are of major importance in prevention and control of infections in burn center ward. [144]

***Enterobacter* spp.**

Enterobacter spp. is significantly responsible for some important nosocomial infections, representing wide MDR through plasmid-encoded ESBLs and KPC carbapenemases, metallo- β -lactamase, even OXA and metallo- β -lactamase-1. Although few antimicrobials such as colistin and tigecycline are influenced by these resistant bacteria and also against many of the other ESKAPE pathogens, there is little or no drugs in the 'pipeline', being remarkably effective in addressing this mounting health crisis. [6,145-146] In veterinary medicine, fluoroquinolone resistance is becoming more common. This Resistance is caused by both chromosomal and plasmid-mediated fluoroquinolone resistance (PMQR) mechanisms which are co-located with other antimicrobial resistance genes including β -lactamases. The genes' relationship with PMQR can cause resistance to fluoroquinolone when joined with topoisomerase mutations and efflux. [147]

In some situations, examination of subsequent strains to find resistance that may have expanded might be warranted before three to four days. The decisions to do so require knowledge of particular condition and the intensity of patient condition such as *Enterobacter cloacae* isolated from a blood culture of premature infants. CLSI protocol to carry out susceptibility experiment on repeat isolates should be defined after negotiation with medical personnel. Some strains of *Citrobacter*, *Providencia* and *Enterobacter* spp. have been presented to give false-susceptible outcomes when tested by disk diffusion with cefdinir and loracaebe strains of these genera should not be examined by disk diffusion with agents. [71]

DISCUSSION

Health crisis of ESKAPE pathogens seems overwhelming. There are comprehensive guidelines for antibiotic resistance control and for a coordinated holistic medicine to uniform industrial and governmental organizations. [4,148-151] In the short run, with treatment options diminishing, it is necessary that the last remaining

antimicrobial agents be protected via intellectual choice and ameliorated infection control. The call for antibiotic superintendence has been mentioned for several years by health authorities to temper the expansion of resistance mechanisms versus the recent persisted antimicrobial agents. [152-154]

Selection of suitable guidelines is readily accessible and accurate prescribing protocols have been successfully implemented worldwide. [155] Prescription of the most suitable antimicrobial agents at the right dose and period, and for an appropriate time has consistently improved sick people outcomes and has decreased antibiotic resistance appearance. [156-157] The campaign of "Clean your hands" in the UK displayed how public intermediation for control of infection one behind another follow with a high profile governmental force can decrease selected HAIs (healthcare-related infections). [158]

In the same case, common notification campaigns, such as the European Antibiotics Awareness Day (EAAD) can support and emphasize the foundation sequences of consecutive antibiotic abuse in both medical profession and in agronomy by the suitable political and financial patronage as the crisis expands and common knowledge enhances. [159]

Louis Pasteur's and Robert Koch's pioneering methodologies appointed the arena of classical microbiology and organized the basis of antimicrobial susceptibility examination over 150 years ago till now. [71,160] However, some microbiologists suggest more complex biofilm manner in distinction for the more lightly reproducible planktonic manner which has mislead research generations. [161,162] Bacterial biofilms provide a distinguished survival benefit versus antimicrobial agents in comparison with their planktonic counterparts, by a 1000-times augmentation in some agents concentration Biofilm development is the underlying basis for persistent HAIs related to installing medical devices in the greater numbers, made possible by ESKAPE pathogens. [163-167] Based on standard guidelines to make proper and practical antibiotic susceptibility testing, the number of agents examined should be confined. CLSI have lists of those agents that perform the fundamental

prescriptions for routine utilization in most clinical laboratories. The tables have columns based on particular organisms or organism groups; several antibiotics are recommended in preference for experiment to help laboratories in their conventional testing batteries selection. This means that major errors are less than 3% and minor errors are fewer than 10%, based on an examination of great collection of accidental clinical strains. Moreover, to determine for an "or word in report of antibiotic susceptibility testing, at least 100 strains with resistance to the agents in question must be examined, and a result of "resistant" must be gained with all agents for at least 95% of the strains. [149]

To sum up, it can be said that healthcare-associated, community-acquired, and nosocomial infections should be carefully considered. In this review, the alarming frequency and increasing tendency of extremely resistant ESKAPE pathogens in the worldwide is highlighted. The awareness of residential antimicrobial resistance can support the selection of a convenient empirical therapeutic diet in which diseases occur due to ESKAPE pathogens. [168]

It should be mentioned that the clinical response of a patient after receiving antibiotic does not always correlate with the laboratory reports. Even so, it should be noted that description of pathogens antimicrobial resistance patterns needs a consecutive update. [128] We must increase hospital infection-control practices for the purpose of restricting the spread of resistance. This procedure will ensure a steady stream of new antibiotics to meet the needs of current patients.

"The authors declare no conflict of interest"

REFERENCES

1. Slavcovicii A, Maier C, Radulescu A. Antimicrobial resistance of ESKAPE-pathogens in culture positive pneumonia. *Farmacia* 2015; 63(2):201-205.
2. Boucher HW, Talbot GH, Bradley JS. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis* 2009; 48: 1-12.
3. Rice LB. Federal Funding for the Study of Antimicrobial Resistance in Nosocomial

- Pathogens: No ESKAPE. *J Infect Dis* 2008; 197: 1079-1081.
4. Pendleton JN, Gorman SP, Gilmore BF. Clinical Relevance of the ESKAPE Pathogens. *Expert Rev Anti Infect Ther* 2013; 11(3):297-308.
5. Rice LB. Progress and challenges in implementing the research on ESKAPE pathogens. *Infect Cont Hos Epidemiol* 2010; 31(1): 7-10.
6. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis* 2009; 48(1): 1–12.
7. Standing Medical Advisory Committee, Sub-Group on Antimicrobial Resistance. The path of least resistance. *J Antimicrob Chemother* 1999; 43 (3): 437-438.
8. http://apps.who.int/iris/bitstream/10665/194460/1/9789241509817_eng.pdf?ua=1 . Antibiotic Resistance: Multi-country public awareness survey. World Health Organization 2015.
9. http://ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf .European Centre for Disease Prevention and Control/European Medicines Agency. ECDC/EMA Joint Technical Report. The bacterial challenge: time to react 2009.
10. http://ec.europa.eu/dgs/health_food-safety/docs/communication_amr_2011_748_en.pdf European Centre for Disease Prevention and Control. Communication from the Commission to the European Parliament and the Council. Action plan against the rising threats from Antimicrobial Resistance.
11. <http://www.idsociety.org/.pdf> Infectious Diseases Society of America. Bad Bugs, No Drugs. As Antibiotic Discovery Stagnates. A Public Health Crisis Brews 2004.
12. Petrosillo N, Capone A, Di Bella S, Taglietti F. Management of antibiotic resistance in the intensive care unit setting. *Expert Rev Anti Infect Ther* 2010; 8(3): 289–302.
13. Rahal JJ. Antimicrobial resistance among and therapeutic options against Gram-negative pathogens. *Clin Infect Dis* 2009; 49(1): 4–10.
14. Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. *Crit Care Med* 2010; 38(8): 1651–1664.
15. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with Gram-negative bacteria. *Clin Microbiol Rev* 2012; 25 (3):450–470.
16. Mouton JW, Van Ogtrop ML, Andes D, Craig WA. Use of pharmacodynamics indices to predict efficacy of combination therapy in vivo. *Antimicrob Agents Chemother* 1999; 43 (10):2473–2478.
17. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant *Pseudomonas aeruginosa*: comparison of risks associated with different antipseudomonal agents. *Antimicrob Agents Chemother* 1999; 43 (6), 1379–1382.
18. Lister PD, Wolter DJ. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of *Pseudomonas aeruginosa*. *Clin Infect Dis* 2005; 40(2): 105–114.
19. Lister PD, Wolter DJ, Wickman PA, Reisbig MD. Levofloxacin/imipenem prevents the emergence of high-level resistance among *Pseudomonas aeruginosa* strains already lacking susceptibility to one or both drugs. *J Antimicrob Chemother* 2006; 57(5): 999–1003.
20. Elphick HE, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. *Cochrane Database Syst Rev* 2005; (2): CD002007.
21. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteremia? A meta-analysis. *Lancet Infect Dis* 2004; 4(8):519–527.
22. Mouton JW, Van Ogtrop ML, Andes D, Craig WA. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. *Antimicrob Agents Chemother* 1999; 43 (10): 2473–2478.
23. Bliziotis IA, Petrosillo N, Michalopoulos A, Samonis G, Falagas ME. Impact of definitive therapy with β -lactam monotherapy or combination with an aminoglycoside or a quinolone for *Pseudomonas aeruginosa* bacteremia. *Plos One* 2011; 6(10): e26470

24. [http:// www.bacterio.cict.fr/e/enterococcus](http://www.bacterio.cict.fr/e/enterococcus). Euze´ P. List of prokaryotic names with standing in nomenclature. Genus *Enterococcus*. 2012.
25. Foulquie´ Moreno MR, Sarantopoulos P, Tsakalidou E, De Vuyst L. The role and application of Enterococci in food and health. *Int J Food Microbiol* 2006; 106:1–24.
26. Sparo M, Nun˜ ez GG, Castro M, Calcagno ML, Garcı´a Allende MA, Ceci M, Najle R, Manghi M. Characteristics of an environmental strain, *Enterococcus faecalis* CECT7121, and its effects as additive on craft dry-fermented sausages. *Food Microbiol* 2008; 25:607–615.
27. Kayser FH. Safety aspects of enterococci from the medical point of view. *Int J Food Microbiol* 2003; 88:255–262.
28. Franz CMAP, Stiles ME, Schleifer KH, Holzapfel WH. Enterococci in foods -A conundrum for food safety. *Int J Food Microbiol* 2003; 88:105–122.
29. de Niederhaˆusern S, Bondi M, Messi P, Iseppi R, Sabia C, Manicardi G, Anacarso I. Vancomycin resistance transfer ability from VanA enterococci to *Staphylococcus aureus*. *Curr Microbiol* 2011; 62:1363–1367.
30. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. *Clin Microbiol Rev* 2000; 13:686–707.
31. Messi P, Guerrieri E, de Niederhaˆusern S, Sabia C, Bondi M. Vancomycin-resistant enterococci (VRE) in meat and environmental samples. *Int J Food Microbiol* 2006; 107:218–222.
32. Ogier JC, Serror P. Safety assessment of dairy microorganisms: The *Enterococcus* genus. *Int J Food Microbiol* 2008; 126:291–301.
33. Delpech G, Pource G, Schell C, De Luca M, Basualdo J, Bernstein J, et al. Antimicrobial Resistance Profiles of *Enterococcus faecalis* and *Enterococcus faecium* isolated from Artisanal Food of Animal Origin in Argentina. *Food Pathogen Dis* 2012; 9(10):1-6.
34. Bourgogne A, Singh KV, Fox KA, Pflughoeft KJ, Murray BE, Garsin DA. EbpR is important for biofilm formation by activating expression of the endocarditis and biofilm-associated pilus operon (ebpABC) of *Enterococcus faecalis* OG1RF. *J Bacteriol* 2007; 189:6490-6493.
35. Giacometti A, Cirioni O, Schimizzi AM, Del Prete MS, Barchiesi F, D'Errico MM, et al. Epidemiology and microbiology of surgical wound infections. *J Clin Microbiol* 2000; 38:918-922.
36. Higaki S, Morohashi M, Yamagishi T. Isolation of *Enterococcus* species from infectious skin lesions. *Drugs Exp Clin Res* 2002; 28:91-93.
37. Bonten MJ, Willems R, Weinstein RA. Vancomycin-resistant enterococci: Why are they here, and where do they come from? *Lancet Infect Dis* 2001; 1:314-325.
38. Adhikari L. High-level aminoglycoside resistance and reduced susceptibility to vancomycin in nosocomial enterococci. *J Glob Infect Dis* 2010; 2:231-235.
39. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. *Clin Microbiol Rev* 2000; 13:686-707.
40. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in *Enterococcus faecium*. *N Engl J Med* 1988; 319:157-1561.
41. Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. *Lancet* 1988; 1:57-58.
42. Murray BE – Vancomycin-resistant enterococcal infections. *N Engl J Med* 2000; 342:710-721.
43. Protonotariou E1, Dimitroulia E, Pournaras S, Pitiriga V, Sofianou D, Tsakris A. Trends in antimicrobial resistance of clinical isolates of *Enterococcus faecalis* and *Enterococcus faecium* in Greece between 2002 and 2007. *J Hosp Infect* 2010; 75:225-227.
44. Sofianou D1, Pournaras S, Giosi M, Polyzou A, Maniatis AN, Tsakris A. Substantially increased *E. faecalis* carriage of vancomycin-resistant enterococci in a tertiary Greek hospital after a 4 year time interval. *J Antimicrob Chemother* 2004; 54:251-254.
45. Souli M, Sakka V, Galani I, Antoniadou A, Galani L, Sifakas N, et al. Colonization with vancomycin- and linezolid-resistant *Enterococcus faecium* in a university hospital: molecular epidemiology and risk factor analysis. *Int J Antimicrob Agents* 2009; 33:137-142.
46. Kang M1, Xie Y, He C, Chen ZX, Guo L, Yang Q, et al. Molecular characteristics of vancomycin-resistant *Enterococcus faecium* from a tertiary care hospital in Chengdu, China. *Eur J Clin Microbiol Infect Dis* 2014; 33(6):933-939.

47. Werner G, Klare I, Fleige C, Geringer U, Witte W, Just HM, et al. Vancomycin-resistant vanB-type Enterococcus faecium isolates expressing varying levels of vancomycin resistance and being highly prevalent among neonatal patients in a single ICU. *Antimicrob Resis Infect Control* 2012; 1:21. doi: 10.1186/2047-2994-1-21
48. Samadi Kafil H, Asgharzadeh M. Vancomycin-Resistant Enterococcus faecium and Enterococcus faecalis isolated from Education Hospital of Iran. *J Clin Med* 2014; 9(4): 323-327.
49. Sedaghat M, Rahimi F, Pourshafie MR, Talebi M. Study of Vancomycin Resistant Enterococcus faecium isolated from clinical samples in Tehran, Iran. *Curr Res Bacteriol* 2012; 5(2): 53-58.
50. Rafiei Tabatabaei S, Karimi A, Navidinia M, Fallah F, Tavakkoly Fard A, Rahbar M. A study on prevalence of vancomycin-resistant enterococci carriers admitted in a children hospital in Iran. *Ann Biol Res* 2012; 3(12): 5441-5445.
51. Nateghian A, Ghasemi Ahari SM, Harahdashti AL, Navidnia M, Mehrazma M. Prevalence of Vancomycin-resistant Enterococci Colonization, and Susceptibility to linezolid in Pediatric Intensive Care Units of a Referral Pediatric Center in Tehran, Iran. *Arch Pediatr Infect Dis* 2014; 2(2): e16970.
52. Sasirekha B. Prevalence of ESBL, AmpC B-lactamases and MRSA among uropathogens and its antibiogram. *Excli J* 2013; 12(1): 81-88.
53. Juyal D, Shamanth AS, Pal S, Sharma MK, Prakash R, Sharma N. The prevalence of inducible clindamycin resistance among staphylococci in a tertiary care hospital - a study from the garhwal hills of uttarakhand, India. *J Clin Diagn Res* 2013; 7(1): 61-65.
54. Ansari MA, Khan H, Khan AA, Pal R, Cameotra SS. Antibacterial potential of Al₂O₃ nanoparticles against multidrug resistance strains of Staphylococcus aureus isolated from skin exudates. *J Nanoparticle Res* 2013; 15(10): 1-12.
55. Sharma N, Singh S, Bains A. Phenotypic and genotypic characterization of MDR isolates of Staphylococcus aureus from urine and sputum in Himachal Pradesh. *Drug Inven Today* 2012; 4(10): 497-500.
56. Mukhiya RK, Shrestha A, Rai SK, Pant K, Rai G, Singh R. Methicillin-resistant Staphylococcus aureus in clinical samples of hospital located in Kathmandu valley, Nepal. *Res J Pharm Biolo Chem Sci* 2013; 4(2): 617-621.
57. <http://www.vdh.virginia.gov>. Virginia department of Health (VDH) : Division of Vital Records and Health Statistics; 2013.
58. Navidinia M, Fallah F, Lajevardi B, Shirdoost M, Jamali J. Epidemiology of Methicillin-Resistant Staphylococcus aureus Isolated From Health Care Providers in Mofid Children Hospital. *Arch Pediatr Infect Dis* 2015; 3(2): e16458.
59. Navidinia M. Detection of inducible clindamycin resistance (MLS_{Bi}) among methicillin-resistant Staphylococcus aureus (MRSA) isolated from health care providers. *J Paramed Sci* 2015; 6(1): 91-96.
60. Jindal N, Singh S, Grover P, Malhotra. Prevalence of Inducible Clindamycin Resistance among Clinical Isolates of MRSA in Malwa Region of Punjab (North India). *Indian J Res* 2013; 2 (10). DOI : 10.15373/22501991
61. Rezaei M, Chavoshzadeh Z, Haroni N, Armin S, Navidinia M, Mansouri M, et al. Colonization with Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Subtypes in Patients with Atopic Dermatitis and Its Relationship with Severity of Eczema. *Arch Pediatr Infect Dis* 2013; 1(2): 53-56.
62. Boguniewicz M, Leung DY. Recent insights into atopic dermatitis and implications for management of infectious complications. *J Allergy Clin Immunol* 2010; 125(1): 4-13.
63. Baker BS. The role of microorganisms in atopic dermatitis. *Clin Exp Immunol* 2006; 144(1): 1-9.
64. Leung AD, Schiltz AM, Hall CF, Liu AH. Severe atopic dermatitis is associated with a high burden of environmental Staphylococcus aureus. *Clin Exp Allergy* 2008; 38(5): 789-793.
65. Cho SH, Strickland I, Tomkinson A, Fehringer AP, Gelfand EW, Leung DY. Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model. *J Invest Dermatol* 2001; 116 (5): 658-663.
66. Guzik TJ, Bzowska M, Kasproicz A, Czerniawska-Mysik G, Wojcik K, Szmyd D, et al. Persistent skin colonization with Staphylococcus aureus in atopic dermatitis: relationship to clinical and immunological parameters. *Clin Exp Allergy*

2005; 35(4):448-455.

67. Gilani SJ, Gonzalez M, Hussain I, Finlay AY, Patel GK. Staphylococcus aureus re-colonization in atopic dermatitis: beyond the skin. Clin Exp Dermatol 2005; 30(1):10-13.

68. Abeck D, Mempel M. Staphylococcus aureus colonization in atopic dermatitis and its therapeutic implications. Br J Dermatol 1998; 139(53):13-16.

69. Higaki S, Morohashi M, Yamagishi T, Hasegawa Y. Comparative study of staphylococci from the skin of atopic dermatitis patients and from healthy subjects. Int J Dermatol 1999; 38(4):265-259.

70. Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 1974; 90(5):525-530.

71. O'Regan GM, Sandilands A, McLean W, Irvine AD. Filaggrin in atopic dermatitis. J Allergy Clin Immunol 2009; 124(3): 2-6.

72. Schaubert J, Gallo RL. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol 2008; 122(2):261-266.

73. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplements 2012, M100-S22; 32 (3):70-88.

74. Petrosillo N, Capone A, Di Bella S, Taglietti F. Management of antibiotic resistance in the intensive care unit setting. Expert Rev Anti Infect Ther 2010; 8(3): 289-302.

75. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009; 9: 228-236.

76. Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother 2008; 52(4): 1413-1418.

77. Pournaras S, Protonotariou E, Voulgari E, Kristo I, Dimitroulia E, Vitti D, et al. Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece. J Antimicrob Chemother 2009; 64(2): 348-352.

78. Bratu S, Mooty N, Nichani S, Landman D, Gullans C, Pettinato B, et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn,

New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother 2005; 49(7): 3018-3020.

79. Srinivasan A, Patel JB. Klebsiella pneumoniae carbapenemase producing organisms: an ounce of prevention really is worth a pound of cure. Infect Control Hosp Epidemiol 2008; 29(12): 1107-1109.

80. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing b-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45(4): 1151-1161.

81. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005; 165(12): 1430-1435.

82. Lomaestro BM, Tobin EH, Shang W, Gootz T. The spread of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae to upstate New York. Clin Infect Dis 2006; 43: e26-8.

83. Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing b-lactamase. Antimicrob Agents Chemother 2007; 51: 1553-1555.

84. Naas T, Nordmann P, Vedel G, Poyart C. Plasmid-mediated carbapenem-hydrolyzing b-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother 2005; 49: 4423-4434.

85. Wei ZQ, Du XX, Yu YS, Shen P, Chen YG, Li LJ. Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. Antimicrob Agents Chemother 2007; 51(2): 763-765.

86. Cuzon G, Naas T, Demachy MC, Nordmann P. Plasmid-mediated carbapenem-hydrolyzing b-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece. Antimicrob Agents Chemother 2008; 52(2): 796-797.

87. Monteiro J, Santos AF, Asensi MD, Peirano G, Gales AC. First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.

- Antimicrob Agents Chemother 2009; 53(1): 333–334.
88. Baraniak A, Izdebski R, Herda M, Fiett J, Hryniewicz W, Gniadkowski M. The emergence of *Klebsiella pneumoniae* ST258 with KPC-2 in Poland. *Antimicrob Agents Chemother* 2009; 53(10): 4565–7567.
89. Samuelsen O, Naseer U, Tofteland S, Skutlaberg DH, Onken A, Hjetland R, et al. Emergence of clonally related *Klebsiella pneumoniae* isolates of sequence type 258 producing plasmid-mediated KPC carbapenemase in Norway and Sweden. *J Antimicrob Chemother* 2009; 63(4): 654–658.
90. Woodford N, Zhang J, Warner M, Kaufmann ME, Matos J, Macdonald A, et al. Arrival of *Klebsiella pneumoniae* producing KPC carbapenemase in the United Kingdom. *J Antimicrob Chemother* 2008; 62 (6): 1261–1264.
91. Akpaka PE, Swanston WH, Ihemere HN, Correa A, Torres JA, Tafur JD, et al. Emergence of KPC-producing *Pseudomonas aeruginosa* in Trinidad and Tobago. *J Clin Microbiol* 2009; 47(8): 2670–2671.
92. Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant *Klebsiella pneumoniae* strains. *Antimicrob Agents Chemother* 2007; 51(8): 3026–3029.
93. Navon-Venezia S, Chmelnitsky I, Leavitt A. Plasmid-Mediated Imipenem-Hydrolyzing Enzyme KPC-2 among Multiple Carbapenem-Resistant *Escherichia coli* Clones. *Antimicrob Agents Chemother* 2006; 50(9): 3098–3101.
94. Naas T, Cuzon G, Villegas MV, Lartigue MF, Quinn JP, Nordmann P. Genetic structures at the origin of acquisition of the β -lactamase blaKPC gene. *Antimicrob Agents Chemother* 2008; 52(4): 1257–1263.
95. Kitchel B, Rasheed JK, Patel JB, Srinivasan A, Navon-Venezia S, Carmeli Y, et al. Molecular epidemiology of KPC-producing *Klebsiella pneumoniae* isolates in the United States: clonal expansion of multilocus sequence type 258. *Antimicrob Agents Chemother* 2009; 53(8): 3365–3370.
96. Hirsch EB, Tam VH. Detection and treatment options for *Klebsiella pneumoniae* carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. *J Antimicrob Chemother* 2010; 1119-1125. doi: 10.1093/jac/dkq108
97. Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004). *Microb Drug Resist* 2006; 12(4): 223–30.
98. Petrosillo N, Giannella M, Lewis R, Viale P. Treatment of Carbapenem-resistant *Klebsiella pneumoniae*: the state of the art. *Expert Rev Anti Infect Ther* 2013; 11(2):159-177.
99. Mobarak MFA, Matbuli RM, Meir H, Gehani NA, ElToukhy AAM, AlQureshey KF, et al. Antimicrobial Resistance Patterns Among *Acinetobacter baumannii* Isolated From King Abdulaziz Hospital, Jeddah, Saudi Arabia, Four-Year Surveillance Study (2010–2013). *Egypt J Med Microbiol* 2014; 23(4):53-60.
100. Fournier PE, Riche H. The Epidemiology and control of *Acinetobacter baumannii* in health Care facilities. *Clin Infect Dis* 2006; 42(5):692-699.
101. Abbo A, Navon-Venezia S, HammerMuntz O, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrug resistant *Acinetobacter baumannii*. *Emerg Infect Dis* 2005; 11(1): 22-29.
102. Montefour K, Frieden J, Hurst S, Helmich C, Headley D, Martin M, et al. *Acinetobacter baumannii* an emerging multidrug-resistant pathogen in critical care. *Crit Care Nurse* 2008; 28(1):15-25.
103. Thuong M, Arvaniti K, Ruimy R, Salmonière P, Scanvic-Hameg A, Lucet JC, et al. Epidemiology of *Pseudomonas aeruginosa* and risk factors for carriage acquisition in an intensive care unit. *J Hosp Infect* 2003; 53(4):274–282.
104. Bergogne-Berezin E, Towner KJ. *Acinetobacter* spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. *Clin Microbiol Rev* 1996; 9(2): 148-165.
105. Surasarang K, Narasawat K, Danchaivijitr S, Rongrungrueng Y. Risk factors for multi-drug resistant *Acinetobacter baumannii* nosocomial infection. *J Med Assoc Thai* 2007; 90(8):1633-1639.
106. Hsueh PR, Teng LJ, Chen CY, Chen WH, Ho SW, Luh KT. Pandrug-resistant *Acinetobacter*

- baumannii causing nosocomial infections in a university hospital, Taiwan. *Emerg Infect Dis* 2002; 8(8): 827–832.
107. Hammer-Muntz O, Krichali T, Siegman-Igra Y, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrug resistant *Acinetobacter baumannii*. *Emerg Infect Dis* 2005; 11(1): 22-29.
108. Corbella X, Montero A, Pujol M, Domínguez MA, Ayats J, Argerich MJ, et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multi-resistant *Acinetobacter baumannii*. *J Clin Microbiol* 2000; 38(11): 4086-4095.
109. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant *Acinetobacter baumannii*. *J Antimicrob Chemother* 2010; 65 (2): 233-238.
110. Matteo Bassetti; Elda Righi; Silvano Esposito; Nicola Petrosillo; Laura Nicolini. Drug Treatment for Multidrug-resistant *Acinetobacter baumannii* Infections. *Future Microbiol* 2008; 3(6):649-660.
111. Bergogne-Berezin E, Towner KJ: *Acinetobacter* spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. *Clin Microbiol Rev* 1996; 9(2):148-165.
112. Fournier PE, Richet H: The epidemiology and control of *Acinetobacter baumannii* in healthcare facilities. *Clin Infect Dis* 2006; 42(5):692-699.
113. Maragakis LL, Perl TM: *Acinetobacter baumannii*: epidemiology, antimicrobial resistance, and treatment options. *Clin Infect Dis* 2008; 46(8): 1254-1263.
114. Fournier P, Vallenet D, Barbe V., Audic S, Ogata H, Poirel L, et al. Comparative genomics of multi-drug resistance in *Acinetobacter baumannii*. *PLoS Genet* 2006. 2: doi: 10.1371/journal.pgen.0020007
115. Chaiwarith R, Mahatthanaphak S, Boonchoo M, Supparatpinyo K, Sirisanthana T. Pandrug-resistant *Acinetobacter baumannii* at Maharaj Nakorn Chiang Mai Hospital. *J Infect Dis Antimicrob Agents* 2005; 22(1):1-8.
116. Saderi H, Owlia P. Detection of Multidrug Resistant (MDR) and Extremely Drug Resistant (XDR) *Pseudomonas Aeruginosa* Isolated from Patients in Tehran, Iran. *Iran J Pathol* 2015; 10(4): 265 – 271.
117. Strateva T, Yordanov D. *Pseudomonas aeruginosa* a phenomenon of bacteria resistance. *J Med Microb* 2009; 58(9): 1133-1148.
118. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in *Acinetobacter* species and *Pseudomonas aeruginosa*. *Clin Infect Dis* 2006; 43 (2): 49-56.
119. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. *Am J Infect Control* 2006; 34(5): 3-10.
120. Hirsch EB, Tam VH. Impact of multidrug resistant *Pseudomonas aeruginosa* infection on patient outcomes. *Expert Rev Pharmacoecon Outcomes Res* 2010; 10(4): 441-451.
121. Morales E, Cots F, Sala M, Comas M, Belvis F, Riu M, et al. Hospital costs of nosocomial multi-drug resistant *Pseudomonas aeruginosa* acquisition. *BMC Health Serv Res* 2012; doi: 10.1186/1472-6963-12-122
122. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 2012; 18 (3): 268-281.
123. Ghazi M, Khanbabaee G, Fallah F, Kazemi B, Mahmoudi S, Navidnia M, et al. Emergence of *Pseudomonas aeruginosa* cross-infection in children with cystic fibrosis attending an Iranian referral pediatric center. *Iran j microbiol* 2012; 4(3) 3: 124-129.
124. Mir TA, Ashraf M, Ahmed K, Chowdhary J, Rehana B, Ahmed J. Clinical profile, diagnostic delay, and genetic make-up of cystic fibrosis in Kashmir, India. *Lung India* 2011; 28(2): 97-100.
125. Hoiby N, Frederiksen B, Pressler T. Eradication of early *Pseudomonas aeruginosa* infection. *J Cyst Fibros* 2005; 4 (2): 49-54.
126. Hoiby N. Recent advances in the treatment of *Pseudomonas aeruginosa*

- infections in cystic fibrosis. *BMC Med* 2011; 9: 32. doi: 10.1186/1741-7015-9-32
127. Bradbury RS, Champion AC, Reid DW. Epidemiology of *Pseudomonas aeruginosa* in a tertiary referral teaching hospital. *J Hosp Infect* 2009; 73(2): 151-156.
128. Falagas ME, Koletsis PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) *Acinetobacter baumannii* and *Pseudomonas aeruginosa*. *J Med Microbiol* 2006; 55(12):1619–1629.
129. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of *Pseudomonas aeruginosa* isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997–1999. *Clin Infect Dis* 2001; 32(2): 146–155.
128. Elizabeth B Hirsch, Vincent H Tam. Impact of multidrug-resistant *Pseudomonas aeruginosa* infection on patient outcomes. *Expert Rev Pharmacoecon Outcomes Res* 2010; 10(4): 441–51.
128. Hirsch EB, Tam VH. Impact of multidrug-resistant *Pseudomonas aeruginosa* infection on patient outcomes. *Expert Rev Pharmacoecon Outcomes Res* 2010; 10(4): 441–451.
129. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. *Clin Infect Dis* 2009; 48(12):1724–1728.
130. Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. *Int J Antimicrob Agents* 2009; 34(5):434–438.
131. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. *Crit Care* 2006; 10(1):R27.
132. Cosgrove SE, Vigliani GA, Fowler VG, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for *Staphylococcus aureus* bacteremia and endocarditis is nephrotoxic. *Clin Infect Dis* 2009; 48(6):713–721.
133. Zavaski AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. *J Antimicrob Chemother* 2007; 60(6):1206–1215.
134. Yuan Z, Tam VH. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. *Expert Opin Investig Drugs* 2008; 17(5):661–668.
135. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. *Lancet Infect Dis* 2006; 6(9):589–601.
136. Bliziotis IA, Petrosillo N, Michalopoulos A, Samonis G, Falagas ME. Impact of definitive therapy with β -lactam monotherapy or combination with an aminoglycoside or a quinolone for *Pseudomonas aeruginosa* bacteremia. *PLoS ONE* 2011; 6(10):e26470.
137. Bodey GP, Jadeja L, Elting L. *Pseudomonas* bacteremia. Retrospective analysis of 410 episodes. *Arch Intern Med* 1985; 145 (9): 1621–1629.
138. Vidal F, Mensa J, Almela M, Martínez JA, Marco F, Casals C, et al. Epidemiology and outcome of *Pseudomonas aeruginosa* bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. *Arch Intern Med* 1996; 156(18):2121–2126.
139. Siegman-Igra Y, Ravona R, Primerman H, Giladi M. *Pseudomonas aeruginosa* bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. *Int J Infect Dis* 1998; 2(4): 211–215.
140. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. β -Lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. *BMJ* 2004; 20;328(7441). doi:10.1136/bmj.38028.520995.63 .
141. Korvick JA, Bryan CS, Farber B, Beam TR Jr, Schenfeld L, Muder RR, et al. Prospective observational study of *Klebsiella* bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy. *Antimicrob Agents Chemother* 1992; 36(12):2639–2644.
142. Jafari M, Fallah F, Borhan RS, Navidinia M, Rafiei Tabatabaei S, Karimi A, et al. The First Report of CMY, aac (6')-Ib and 16S rRNA Methylase Genes Among *Pseudomonas* Isolates

- From Iran. Arch Pediatr Infect Dis 2013; 1(3): 109-112.
- 143.<http://tinyurl.com/crww3gg>. Health Protection Agency. Enterobacter species.
144. Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, Mendes RE. Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006–2007. Antimicrob Agents Chemother 2011; 55(3), 1274–1278.
147. Gibson JS, Cobbold RN, Heisig P, Sidjabat HE, Kyaw-Tannera MT, Trotta DJ. Identification of Qnr and AAC (6′)-Ib-cr plasmid-mediated fluoroquinolone resistance determinants in multidrug-resistant Enterobacter spp. isolated from extraintestinal infections in companion animals. Vet Microbiol 2010; 143(14):329–336.
148. WHO: WHO Global Strategy for Containment of Antimicrobial Resistance. WHO/CDS/CSR/DRS/2001.2 (2001).
149. European Centre for Disease Prevention and Control. Communication from the Commission to the European Parliament and the Council. Action plan against the rising threats from Antimicrobial Resistance. COM 748 (2011)
- 150.<http://tinyurl.com/blhxofz>. WHO. The evolving threat of antimicrobial resistance – options for action (2012).
151. National Institute for Health and Clinical Excellence. NICE public health guidance 36 – prevention and control of healthcare associated infections. PH36 (2011).
152. Standing Medical Advisory Committee, Sub-Group on Antimicrobial Resistance. The path of least resistance. (1998).
- 153.http://www.who.int/drugresistance/WHO_Global_Strategy_English.pdf WHO: Department of Communicable Disease Surveillance and Response. WHO Global Strategy for Containment of Antimicrobial Resistance. WHO/CDS/CSR/DRS/2001.2 (2001).
- 154.<http://www.idsociety.org/> Infectious Diseases Society of America. Bad Bugs, No Drugs. As Antibiotic Discovery Stagnates. A Public Health Crisis Brews. (2004).
- 155.<http://tinyurl.com/c999mvd>. Centers for Disease Control and Prevention. Antimicrobial Stewardship for the community hospital: practical tools and techniques for implementation.
156. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44(2):159–177.
- 157.<https://www.gov.uk/> Department of Health Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection (ARHAI). Antimicrobial Stewardship: 'Start Smart – Then Focus' (2011).
158. Stone SP, Fuller C, Savage J, Cookson B, Hayward A, Cooper B, et al. Evaluation of the national Clean your hands campaign to reduce Staphylococcus aureus bacteremia and Clostridium difficile infection in hospitals in England and Wales by improved hand hygiene: four year, prospective, ecological, interrupted time series study. BMJ 2012; 344, e3005. doi: 10.1136/bmj.e3005.
- 159.<http://antibiotic.ecdc.europa.eu>. European Centre for Disease Prevention and Control. European Antibiotic Awareness Day the currency, frequency and identification of such campaigns are presumably to proliferate. (2011)
160. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001; 48(1): 5–16.
161. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2004; 2(2): 95–108.
162. Costerton JW. Introduction to biofilm. Int J Antimicrob Agents 1999; 11(3–4):217–221.
163. Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov 2003; 2(2): 114–122.
164. Ceri H, Olson ME, Turner RJ. Needed, new paradigms in antibiotic development. Expert Opin Pharmacother 2010; 11(8): 1233–1237.
165. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284(5418): 1318–1322.
166. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002; 15(2): 194–222.
167. Parsek MR, Singh PK. Bacterial biofilms: an emerging link to disease pathogenesis. Annu Rev Microbiol 2003; 57(1): 677–701.

168.Slavcovici A, Maier C, Radulescu A.
Antimicrobial Resistance of ESKAPE-Pathogens
in Culture-Positive Pneumonia. *Farmacia* 2015;
63(2):201-205.